Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or OpenAthens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Review Article

Free Access

Pharmacological Treatment of Apathy in Neurodegenerative Diseases: A Systematic Review

Drijgers R.L.a, c · Aalten P.a, c · Winogrodzka A.b · Verhey F.R.J.a, c · Leentjens A.F.G.a, c

Author affiliations

Departments of aPsychiatry and bNeurology, Maastricht University Medical Centre, and cAlzheimer Center Limburg, Maastricht, The Netherlands

Corresponding Author

Albert F.G. Leentjens

Department of Psychiatry

Maastricht University Medical Centre, PO Box 5800

NL–6202 AZ Maastricht (The Netherlands)

Tel. +31 43 387 7443, Fax +31 43 387 5444, E-Mail a.leentjens@np.unimaas.nl

Related Articles for ""

Dement Geriatr Cogn Disord 2009;28:13–22

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Objective: To evaluate the efficacy of pharmacological treatment of apathy in patients with neurodegenerative diseases. Methods: Systematic review of studies assessing the effects of pharmacological treatment on apathy in neurodegenerative diseases. Results: Thirty-five studies were included: 2 meta-analyses, 13 randomized controlled trials (RCTs), 14 open-label studies, 5 case series, and 1 single case study. Eight studies included apathy as a primary outcome. A cholinesterase inhibitor was investigated in 24 studies, methylphenidate in 5, and other medications in 6 studies. Most RCTs of cholinesterase inhibitors reported a small but statistically significant improvement of apathetic symptoms. Conclusions: Although some medications are promising candidates for further study, there is as yet insufficient evidence that pharmacological treatment improves apathetic symptoms in patients with neurodegenerative disease. Large-scale, placebo-controlled RCTs with apathy as a primary outcome measure are needed to establish the potential benefit of pharmacological treatment of apathy.

© 2009 S. Karger AG, Basel


  1. Starkstein SE, Leentjens AFG: The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry 2008;79:1088–1092.
  2. Mega MS, Cummings JL, Fiorello T, Gornbein J: The spectrum of behavioral changes in Alzheimer’s disease. Neurology 1996;46: 130–135.
  3. Boyle PA, Malloy PF: Treating apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2004;17:91–99.
  4. Landes AM, Sperry SD, Strauss ME, Geldmacher DS: Apathy in Alzheimer’s disease. J Am Geriatr Soc 2001;49:1700–1707.
  5. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, Breitner JC, Steffens DC, Tschanz JT; Cache County Investigators: Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008;23:170–177.
  6. Aalten P, de Vugt ME, Jaspers N, Jolles J, Verhey FRJ: The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry 2005;20:523–530.
  7. Dujardin K, Sockeel P, Devos D, Delliaux M, Krystkowiak P, Destee A, Defebvre L: Characteristics of apathy in Parkinson’s disease. Mov Disord, 2007;22:778–784.
  8. Pluck GC, Brown RG: Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73:636–642.
  9. Sockeel P, Dujardin K, Devos D, Deneve C, Destee A, Defebvre L: The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006;77:579–584.
  10. Leentjens A, Dujardin K, Marsh L, Martinez-Martin P, Richard I, Starkstein S, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins G, Goetz C: Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 2008; 23:2004–2014.
  11. Brown RG, Pluck G: Negative symptoms: the ‘pathology’ of motivation and goal-directed behaviour. Trends Neurosci 2000;23:412–417.
  12. Finkel S: The significance of the behavioural and psychological symptoms of dementia. Clinician 1998;16:33–42.
  13. Chan DC, Kasper JD, Black BS, Rabins PV: Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis. J Gerontol A Biol Sci Med Sci 2003;58:548–554.
  14. Shin I, Carter M, Masterman D, Fairbanks L, Cummings JL: Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry 2005;13:469–474.
  15. de Vugt ME, Stevens F, Aalten P, Lousberg R, Jaspers N, Winkers I, Jolles J, Verhey FR: Behavioural disturbances in dementia patients and quality of the marital relationship. Int J Geriatr Psychiatry 2003;18:149–154.
  16. Onyike CU, Sheppard JM, Tschanz JT, Norton MC, Green RC, Steinberg M, Welsh-Bohmer KA, Breitner JC, Lyketsos CG: Epidemiology of apathy in older adults: the Cache County Study. Am J Geriatr Psychiatry 2007;15:365–375.
  17. Yeager C, Hyer L: Apathy in dementia: relations with depression, functional competence, and quality of life. Psychol Rep 2008;102:718–722.
  18. Aarsland D, Larsen J, Lim N, Janvin C, Karlsen K, Tandberg E, Cummings J: Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999;67:492–496.
  19. Levy M, Cummings J, Fairbanks L, Masterman D, Miller B, Craig AH, Paulsen JS, Litvan I: Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998;10:314–319.
  20. Isella V, Melzi P, Grimaldi M, Iurlaro S, Piolti R, Ferrarese C, Frattola L, Appollonio I: Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease. Mov Disord 2002;17:366–371.
  21. Politis AM, Vozzella S, Mayer LS, Onyike CU, Baker AS, Lyketsos CG: A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. Int J Geriatr Psychiatry 2004;19:1087–1094.
  22. Chapman S, Weiner M, Rackley A, Hynan L, Zientz J: Effects of cognitive-communication stimulation for Alzheimer’s disease patients treated with donepezil. J Speech Lang Hear Res 2004;47:1149–1163.
  23. Chung J, Lai C, Chung P, French H: Snoezelen for dementia. Cochrane Database Syst Rev 2002;4:CD003152.
  24. Hirakawa Y, Masuda Y, Kimata T: Effects of home massage rehabilitation therapy for the bed-ridden elderly: a pilot trial with a three-month follow-up. Clinical Rehabilitation 2005;19:20–27.
  25. Medicine OCfE-b: Levels of evidence and grades of recommendation. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/levels_of_evidence (May, 2001).
  26. Phillips B, Ball C, Badenoch D, Straus S, Haynes B, Dawes M: Levels of evidence. BJU International 2008;101:932.
    External Resources
  27. Cummings JL, Mega, M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.
  28. Cohen J: Statistical Power Analysis for the Behavioral Sciences. Hillsdale, Lawrence Earlbaum Associates, 1988.
  29. Cummings JL, Nadal A, Masterman D, Cyrus P: Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol 2001;14:101–108.
  30. Morris J, Cyrus P, Orazem J, Mas J, Bieber F, Ruzicka B, Gulanski B: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology 1998;50:1222–1230.
  31. Raskind M, Cyrus P, Ruzicka B, Gulanski B: The effects of metrifonate on the cognitive, behavioural, and funtional performance of Alzheimer’s disease patients. J Clin Psychiatry 1999;60:318–325.
  32. Herrmann N, Rabheru K, Wang J, Binder C: Galantamine treatment of problematic behavior in Alzheimer’s disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 2005;13:527–534.
  33. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D: Effects of a flexible galantamine dose in Alzheimer’s disease: a randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589–595.
  34. Tariot P, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269–2276.
  35. Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, Lanctot KL: Methylphenidate for the treatment of apathy in Alzheimer disease. J Clin Psychopharmacol 2008;28:296–301.
  36. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143–162.
  37. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, Richardson S: Efficacy of donepezil in early-stage Alzheimer disease. Arch Neurol 2004;61:1852–1856.
  38. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG: Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992;4:134–139.
  39. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001;57:613–620.
  40. Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni J, Schwam E: Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized placebo-controlled trial. Int J Geriatr Psychiatry 2005;20:559–569.
  41. Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B: Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr 2002;14:389–404.
  42. Folstein M, Folstein S, McHugh P: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  43. Tariot P, Cummings JL, Katz IR, Mintzer J, Perdomo C, Schwam E: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001;49: 1590–1599.
  44. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A: The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214–219.
  45. Kaufer D: Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9:8–14.
  46. Dubois B, McKeith I, Orgogozo J, Collins O, Meulien D: A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer’s disease: the MALT study. Int J Geriatr Psychiatry 1999; 14:973–982.
  47. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrera R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000;356:2031–2036.
  48. Erkinjuntii T, Kurz A, Gauthier S: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomized trial. Lancet 2002;359:1283–1290.
  49. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ: Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology 2004;172:400–408.
  50. Scripnikov A, Khomenko A, Napryenyenko O: Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomized controlled trial. Wien Med Wochenschr 2007;157:295–300.
  51. Gauthier S, Juby A, Rehel B, Schecter R: EXACT: rivastigmine improves high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer’s disease. Int J Clin Pract 2007;61:886–895.
  52. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B: Motivation, reward, and Parkinson’s disease: influence of dopatherapy. Neuropsychologia 2002;40:2257–2267.
  53. McKeith I, Crace J, Walker Z, Byrne E, Wilkinson D, Stevens T, Perry E: Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000;15:387–392.
  54. Dartigues J, Goulley F, Bourdeix I, Pere J, Barberger-Gateau P: Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer’s disease. Rev Neurol 2002;158:807–812.
  55. Cummings JL, Koumaras B, Chen M, Mirski D: Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Psychiatry 2005;3:137–148.
  56. Mega M, Masterman D, O’Connor S, Barclay T, Cummings JL: The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388–1393.
  57. Tanaka M, Namiki C, Thuy D, Yoshida H, Kawasaki K, Hashikawa K: Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer’s disease. J Neurol Sci 2004;225:135–141.
  58. Rockwood K, Black S, Bedard M, Tran T, Lussier I; TOPS Study Investigators: Specific symptomatic changes following donepezil treatment of Alzheimer’s disease: a multi-centre, primary care, open-label study. Int J Geriatr Psychiatry 2007;22:312–319.
  59. Edwards K, Hershey L, Wray L, Bednarczyk E, Lichter D, Farlow M, Johnson S: Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord 2004;17:40–48.
  60. Brodaty H, Woodward M, Barnes N, Allen G: A naturalistic study of galantamine for Alzheimer’s disease. CNS Drugs 2006;20: 935–943.
  61. Kaufer D, Cummings JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1–6.
  62. Kaufer D, Cummings JL, Christine D: Differential neuropsychiatric symptom response to tacrine in Alzheimer’s disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998;10:55–63.
  63. Galynker I, Ieronimo C, Miner C, Rosenblum J, Vilkas N, Rosenthal R: Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 1997;9:231–239.
  64. Andreasen N: Scale for the Assesment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983.
  65. Levin O: Coaxil (tianeptine) in the treatment of depression in Parkinson’s disease. Neurosci Behav Physiol 2007;37:419–424.
  66. Jansen IH, Olde Rikkert MG, Hulsbos HA, Hoefnagels WH: Toward individualized evidence-based medicine: five ‘N of 1’ trials of methylphenidate in geriatric patients. J Am Geriatr Soc 2001;49:474–476.
  67. Fahn S, Elton RL: Unified Parkinson’s Disease Rating Scale. Florham Park, McMillan Health Care Information, New Jersey, 1987.
  68. Chatterjee A, Fahn S: Methylphenidate treats apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2002;14:461–462.
  69. Padala R, Burke WJ, Bhatia SC, Petty F: Treatment of apathy with methylphenidate. J Neuropsychiatry Clin Neurosci 2007;19:81–83.
  70. Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B: Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 1995;7:23–30.
  71. Lanctot KL, Herrmann N: Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry 2000;15:338–345.
  72. Swanberg M: Memantine for behavioral disturbances in frontotemporal dementia, a case series. Alzheimer Dis Assoc Disord 2007;21:164–166.
  73. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia, a review of the evidence. JAMA 2005;293:596–608.
  74. Robert PH, Onyike CU, Leentjes AFG, Dujardin K, Aalten P, Starkstein SE, Verhey FR, Yessavage J, Clement JP, Drapier D, Bayle F, Benoit M, Boyer P, Lorca PM, Thibaut F, Gauthier S, Grossberg G, Vellas B, Byrne J: Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry 2009;24:98–104.

Article / Publication Details

First-Page Preview
Abstract of Review Article

Accepted: May 20, 2009
Published online: July 17, 2009
Issue release date: August 2009

Number of Print Pages: 10
Number of Figures: 0
Number of Tables: 2

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.